OakChart

Oramed Pharmaceuticals Inc

ORMPHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 7:26 AM ET

4.01+0.04 (1.01%)
2026-11-11 15:00 CET
Market cap
165.14 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
174.06 USD m
Free cash flow, TTM
-5.82 USD m
EPS diluted, TTM
4.11
P/E
0.98
Compare

Price

ORMP against its 20, 50 and 200-day averages
2050200beatearnings
3.004.005.002.1M4.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ORMPclose 4.0120-day 4.0750-day 4.40200-day 4.054.01

26.7% under 5.47 on 27 Aug 2026. Last 15 sessions, 11.7% high to low

Profile

ORMP
52-week range, 57% of the way up
2.085.47

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

IndexRUT
Employees13
IPOMar 19, 2004
Beta1.29
ATR, 14d0.15
Rel volume2.15
Short float4.29%
Insider own24.68%
Inst own40.62%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap166.80M
Enterprise Value116.92M
Income174.06M
Sales0.00M
Book/sh7.68
Cash/sh1.22
Dividend Est.-
Dividend TTM-
Dividend Ex-DateJan 16, 2026
Dividend Gr. 3/5Y- -
Payout0.00%
Employees13
IPOMar 19, 2004

Ratios

P/E0.98
Forward P/E-
PEG-
P/S-
P/B0.52
P/C3.30
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio4.98
Current Ratio4.98
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)4.11
EPS next Y-
EPS next Q0.43
EPS this Y246.51%
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y-9.55% -5.90%
EPS Y/Y TTM802.72%
Sales Y/Y TTM-100.00%
EPS Q/Q489.58%
Sales Q/Q-
EarningsAug 12
EPS/Sales Surpr.541.86% -

Ownership

Insider Own24.68%
Insider Trans-2.47%
Inst Own40.62%
Inst Trans11.93%
ROA65.52%
ROE73.75%
ROIC54.74%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-1.53%
SMA50-8.92%
SMA200-1.01%
Trades-

Technical

Shs Outstand41.31M
Shs Float31.33M
Short Float4.29%
Short Ratio7.73
Short Interest1.34M
52W High5.47 -26.69%
52W Low2.08 92.58%
Volatility3.84% 3.60%
ATR (14)0.15
RSI (14)42.70
Beta1.29
Rel Volume2.15
Avg Volume173.82K
Volume18,705

Performance

Perf Week-2.91%
Perf Month-3.84%
Perf Quarter-8.45%
Perf Half Y-12.06%
Perf YTD50.93%
Perf Year77.74%
Perf 3Y124.03%
Perf 5Y-84.59%
Perf 10Y-31.40%
Recom3.00
Target Price7.00
Prev Close3.97
Price4.01
Change %1.01%

Analyst ratings

latest 10 of 16
DateActionAnalystRating changeTargetImplied
Jan 12, 2023DowngradeCCanaccord GenuityBuy → Hold$30 → $3-25.2%
Feb 18, 2022InitiatedCCantor FitzgeraldOverweight$20+398.8%
Apr 20, 2021InitiatedCCanaccord GenuityBuy$27+573.3%
Feb 09, 2021InitiatedNNational SecuritiesBuy
Dec 03, 2020InitiatedAAlliance Global PartnersBuy$11+174.3%
Mar 11, 2020InitiatedAAegis CapitalBuy$5.50+37.2%
Sep 11, 2019InitiatedLLadenburg ThalmannBuy$7+74.6%
Dec 11, 2017ResumedBB. Riley FBR, Inc.Buy$20+398.8%
May 26, 2016ReiteratedFFBR CapitalOutperform$15 → $20+398.8%
Dec 01, 2015ReiteratedHH.C. WainwrightBuy$24 → $25+523.4%

Peers

Mkt cap
TickerCompanyMkt cap
RANIRani Therapeutics Holdings Inc81.86M
ENTXEntera Bio Ltd546.80M
MNKDMannkind Corp1.36B
VANIVivani Medical Inc103.87M
LFWDLifeward Ltd16.55M
GPCRStructure Therapeutics Inc ADR1.58B
BMEABiomea Fusion Inc39.14M
NVONovo Nordisk ADR135.84B
LLYLilly(Eli) & Co1330.40B
SCLXScilex Holding Company11.33M

Insider trading

13 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Gabay AvrahamChief Financial OfficerOct 01 '26Sale4.5120,00090,200861,076Oct 02 05:19 PM
Hexter JoshuaCOO & CBOOct 01 '26Sale4.5130,000135,3301,328,130Oct 02 05:19 PM
Avi GabayOfficerOct 01 '26Proposed Sale4.6720,00093,400Oct 01 07:43 AM
Joshua HexterOfficerOct 01 '26Proposed Sale4.6730,000140,100Oct 01 07:38 AM
Hexter JoshuaCOO & CBOJul 02 '26Option Exercise3.6950,000184,5001,073,384Jul 02 05:00 PM
Hexter JoshuaCOO & CBOJul 01 '26Sale4.46137,000611,4311,023,384Jul 02 05:00 PM
Gabay AvrahamChief Financial OfficerJul 01 '26Sale4.5173,360330,744671,785Jul 02 05:00 PM
Hexter JoshuaOfficerJul 01 '26Proposed Sale4.81137,000658,970Jul 01 12:03 PM
Gabay AvrahamOfficerJul 01 '26Proposed Sale4.8193,360449,062Jul 01 11:47 AM
Hexter JoshuaCOO & CBOJan 22 '26Option Exercise0.0019,00001,064,495Jan 29 04:05 PM
Kidron MiriamChief Scientific OfficerJan 22 '26Option Exercise0.0019,00001,448,664Jan 29 04:05 PM
Gabay AvrahamChief Financial OfficerJan 22 '26Option Exercise0.0019,0000649,256Jan 29 04:05 PM
KIDRON NADAVPresident and CEOJan 22 '26Option Exercise0.00109,00003,355,238Jan 29 04:05 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFAUM: 1.06B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
DFACU.S. Core Equity 2 Portfolio-ETF Class Shares-
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B
RSSLGlobal X Russell 2000 ETFAUM: 1.43B

News

latest 14 of 206
  • Oramed: Q2 Earnings Snapshot (Associated Press)
  • Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet (PR Newswire) +16.28%
  • Oramed Pharmaceuticals to Join Russell 2000 and Russell 3000 Indexes (PR Newswire)
  • Oramed: Q1 Earnings Snapshot (Associated Press)
  • Oramed: Q4 Earnings Snapshot (Associated Press Finance) -5.14%
  • Loading…
  • Oramed and Lifeward Announce Strategic Transaction (PR Newswire)
  • Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments (PR Newswire) +6.51%
  • Oramed Reports Fiscal Third Quarter 2025 Financial Results (PR Newswire)
  • ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS (PR Newswire)
  • Oramed: Q3 Earnings Snapshot (Associated Press Finance)
  • Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives (PR Newswire)
  • Oramed: Q2 Earnings Snapshot (Associated Press Finance)
  • Oramed: Q1 Earnings Snapshot (Associated Press Finance)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-122.7600.4302.7600.000.001
2026Q12026-06-030.910-0.9100.00--
2025Q42026-02-250.000-0.2270.00--
2025Q22025-08-13-0.040-0.0400.3120.000.001
2025Q12025-05-28-0.190-0.010-0.1852.000.001
2024Q42025-02-26-0.250-0.020-0.2550.000.001
2024Q32024-11-08-0.4800.005-0.4800.000.002
2024Q22024-08-070.2200.0100.2220.000.252
2024Q12024-05-290.0400.0400.0370.000.002
2023Q42024-02-280.325-0.1200.3300.000.002
2023Q32023-11-10-0.080-0.085-0.0800.000.702
2023Q22023-08-09-0.030-0.100-0.0300.700.703
2023Q12023-05-11-0.080-0.260-0.0850.690.753
2022Q42023-03-06-0.220-0.228-0.2160.680.725
2025Q3---0.0401.131-0.001
2026Q3--0.430--0.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2014FY-0.620-0.640-0.00-
2015FY-0.667-0.670-0.670--
2017FY-0.787-0.780-0.7902.462.46
2018FY-0.850-0.950-0.8602.432.44
2019FY-0.820-0.900-0.8222.702.70
2020FY-0.558-0.797-0.5612.714.37
2021FY-0.788-0.804-0.7802.702.92
2022FY-0.925-0.936-0.9382.752.77
2023FY0.135-0.3150.1361.321.32
2024FY-0.480-0.240-0.4670.000.00
2025FY1.290-1.2902.00-
2026FY-4.470--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-121000.000.000.00
2026Q3S2026-06-051000.000.000.00
2026Q3R2026-11-101000.430.430.43
2026Q3R2026-08-271010.430.430.43
2026Q3R2026-08-121100.520.520.52
2026Q3R2026-06-171100.520.520.52
2026Q3R2026-06-051000.190.190.19
2026Q3E2026-11-101000.430.430.43
2026Q3E2026-08-271010.430.430.43
2026Q3E2026-08-121100.520.520.52
2026Q3E2026-06-171100.520.520.52
2026Q3E2026-06-051000.190.190.19
2026Q2S2026-06-051000.000.000.00
2026Q2R2026-08-271102.762.762.76

Estimate history

EPS, annual-0.87-0.79-0.86-0.822-0.561-0.9380.136-0.4671.4994.1105
Period201620172018201920202022202320242025TTM
EPS, quarterly0.222-0.48-0.255-0.1850.3121.1310.2270.9131.839
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.6412.4562.4492.7032.712.7031.34020
Period201620172018201920202022202320242025TTM
Sales, quarterly000200000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual13.18313.66917.3717.38323.67639.56440.33939.9239.27541.314
Period201620172018201920202022202320242025MRQ
Shares, quarterly40.62940.2139.9240.8540.84540.83839.27540.92641.314
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2020FY2019FY2018FY
Total Revenue0.002.000.001.342.70-2.712.702.45
Cost of Goods Sold Incl. D&A0.121.990.19----0.09-0.08
Gross Profit-0.120.01-0.19----2.612.53
Selling, General and Administrative Excl. Other14.4015.1012.5916.9143.24-14.4617.2416.06
Research and Development4.746.386.328.7827.58-10.2313.5211.98
Other Operating Expense0.000.000.000.000.00-0.000.000.00
Operating Income-14.52-15.09-12.78-15.77-40.60--11.76-14.63-13.53
Interest Expense-0.000.853.580.01-0.000.000.01
Unusual Expense-184.67-88.010.00-16.390.76-0.00--
Net Income Before Taxes220.2875.32-15.925.09-37.66--11.51-14.06-12.73
Income Taxes45.4111.313.180.000.10-0.000.300.00
Consolidated Net Income174.0663.21-19.105.09-37.76--11.51-14.36-12.73
Net Income From Continuing Operations174.0663.24-19.065.53-36.56--11.51-14.36-12.73
Net Income174.0663.24-19.065.53-36.56--11.51-14.36-12.73
EPS (Recurring)1.050.05-0.47-0.15-0.92--0.56-0.82-0.86
EPS (Basic, Before Extraordinaries)4.231.53-0.470.14-0.94--0.56-0.82-0.86
EPS (Diluted)4.111.50-0.470.14-0.94--0.56-0.82-0.86
EBITDA-14.40-14.97-12.59-15.57-40.54--11.75-14.62-13.52
Non-Operating Income (Expense)50.132.40-2.298.053.71-0.250.580.81
Other After Tax Adjustments-0.81-0.810.000.000.00-0.000.000.00
Stock Option Compensation Expense3.084.073.206.558.86-1.170.621.18
Price To Earnings Ratio0.970.9722.20------
Price To Sales Ratio-60.45-69.93173.56-26.4421.4430.08
Gross Margin-0.65-----96.67103.27
Operating Margin--754.40--1,176.79-1,501.96--433.84-541.29-552.35
Net Margin-3,162.10-412.31-1,352.61--424.76-531.08-519.68
Shares Outstanding41.3139.2839.9240.3439.56-23.6817.3817.37
Market Capitalization165.14165.1497.5693.18470.55-82.1157.7185.95

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.002.000.000.00
Cost of Goods Sold Incl. D&A0.030.030.030.030.032.020.030.05
Gross Profit-0.03-0.03-0.03-0.03-0.03-0.02-0.03-0.05
Selling, General and Administrative Excl. Other2.743.635.642.402.464.483.563.04
Research and Development0.001.591.991.151.032.211.462.24
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.77-3.66-5.67-2.43-2.49-4.50-3.60-3.09
Interest Expense--0.00-----
Unusual Expense-103.67-44.81-16.23-19.96-7.140.000.000.00
Net Income Before Taxes101.5949.449.8059.4513.13-7.06-9.78-18.51
Income Taxes23.4311.13-0.2111.06-0.130.580.421.13
Consolidated Net Income78.1638.319.2048.3913.26-7.64-10.20-19.64
Net Income From Continuing Operations78.1638.319.2048.4013.29-7.64-10.19-19.62
Net Income78.1638.319.2048.4013.29-7.64-10.19-19.62
EPS (Recurring)0.130.17-0.050.800.19-0.19-0.26-0.48
EPS (Basic, Before Extraordinaries)1.900.940.231.160.32-0.19-0.26-0.48
EPS (Diluted)1.840.910.231.130.31-0.19-0.26-0.48
EBITDA-2.73-3.63-5.64-2.40-2.46-4.47-3.56-3.04
Non-Operating Income (Expense)0.698.29-0.7641.918.49-2.56-6.19-15.42
Other After Tax Adjustments0.000.00-0.810.000.000.000.000.00
Stock Option Compensation Expense0.001.371.140.570.630.160.970.24
Price To Earnings Ratio0.972.292.84---22.2022.39
Price To Sales Ratio--57.6456.4647.9444.11--
Gross Margin------0.85--
Operating Margin------225.00--
Net Margin------382.10--
Shares Outstanding41.3140.9339.2840.8440.8540.8539.9240.21
Market Capitalization165.14137.52113.44108.2591.9186.2797.5699.48

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments125.89141.93162.05155.72-39.9032.2830.4620.10
Short Term Receivables0.000.000.000.00-0.000.00-0.04
Inventories0.000.000.000.00-0.000.000.000.00
Other Current Assets7.381.290.541.39-0.611.040.570.16
Total Current Assets133.27143.22162.58157.11-40.5133.3231.0420.30
Net Property, Plant & Equipment1.341.111.571.80-0.170.020.020.02
Total Investments and Advances96.2110.9156.372.70-3.931.2916.3318.38
Intangible Assets0.000.000.000.00-0.000.000.000.00
Other Assets0.050.030.030.03-0.020.020.020.01
Total Assets230.86155.28220.55161.64-44.6334.6647.4038.71
Short Term Debt Incl. Current Port. of LT Debt0.280.2251.280.25-0.040.000.000.00
Accounts Payable0.440.790.552.17-0.591.341.142.72
Income Tax Payable3.293.20-------
Other Current Liabilities15.071.481.383.32-3.903.973.422.45
Total Current Liabilities19.095.6853.215.75-4.545.314.555.17
Long Term Debt0.540.160.340.65-0.030.000.000.00
Provision for Risks Charges0.040.030.040.03-0.030.030.030.03
Deferred Tax Liabilities7.91--------
Other Liabilities3.544.064.064.06-7.169.9311.7014.28
Total Liabilities31.129.9357.6610.49-11.7515.2716.2919.47
Non-Equity Reserves0.000.000.000.00-0.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.00-0.000.000.000.00
Common Equity199.74146.26163.82151.81-32.8819.3931.1119.24
Total Shareholders Equity199.74146.26163.82151.81-32.8819.3931.1119.24
Accumulated Minority Interest0.00-0.92-0.93-0.66-0.000.000.000.00
Total Equity199.74145.35162.89151.16-32.8819.3931.1119.24
Total Liabilities & Stockholders Equity230.86155.28220.55161.64-44.6334.6647.4038.71
Book Value Per Share5.093.664.063.84-1.391.121.791.41
Tangible Book Value Per Share5.093.664.063.84-1.391.121.791.41
Full-Time Employees13131517-12131314
Price to Book Ratio0.520.620.623.06-2.512.682.766.15
Return on Assets32.76-10.142.89-25.25--29.03-34.99-29.56-25.70
Return on Equity36.56-12.293.50-27.33--44.04-56.85-50.55-46.14
Return on Invested Capital31.58-13.023.37-23.98--34.98-74.02-40.91-54.48
Quick Ratio6.9825.193.0627.34-8.936.286.823.93
Current Ratio6.9825.193.0627.34-8.936.286.823.93

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2020FY2019FY2018FY
Net Income181.7164.02-19.105.09-37.76--11.51-14.36-12.73
Depreciation0.130.120.190.200.06-0.010.010.01
Other Funds (Non Cash)-230.45-79.297.30-12.889.95-2.221.121.67
Funds from Operations-7.77-7.24-11.61-7.60-27.76--9.28-13.23-11.05
Extraordinary Item0.000.000.000.000.00-0.000.000.00
Changes in Working Capital1.96-1.913.20-2.70-0.94--3.160.29-3.60
Cash from Operating Activities-5.81-9.15-8.41-10.30-28.70--12.44-12.94-14.66
Capital Expenditures-0.01-0.01-0.02-0.25-0.50--0.08-0.02-0.01
Net Assets From Acquisitions0.000.000.000.000.00-0.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.02-0.000.000.00
Purchase or Sale of Investments22.818.45105.90-72.7830.68-4.7115.51-7.00
Purchase of Investments-71.09-94.68-55.76-190.92-154.41--39.38-26.35-26.57
Sale Or Maturity of Investments93.90103.13161.65118.14185.09-44.0941.8619.57
Other Uses-1.22-3.00-0.070.000.00--0.00-4.24-0.00
Other Sources0.000.000.010.000.00-0.000.000.00
Cash from Investing Activities21.575.44105.82-73.0430.21-4.6311.26-7.00
Cash Dividends Paid0.000.000.000.000.00-0.000.000.00
Change in Capital Stock-4.66-4.74-2.482.4311.56-23.790.0022.65
Repurchase of Common Pref Stock-4.66-4.74-2.480.000.00-0.000.000.00
Sale of Common Pref Stock0.000.000.002.4311.56-23.790.0022.65
Proceedsfrom Stock Options0.000.000.002.4311.50-23.770.0021.66
Issuance or Reduction of Debt, Net-10.710.00-49.5549.550.00-0.000.000.00
Change in Long Term Debt0.000.000.000.000.00-0.000.000.00
Issuance of Long Term Debt0.000.000.000.000.00-0.000.000.00
Reduction of Long Term Debt0.000.000.000.000.00-0.000.000.00
Net Financing Active Other Cash Flow-1.920.00-0.000.000.00-0.000.000.00
Other Financing Activities Uses-1.920.00-0.000.000.00-0.000.000.00
Cash from Financing Activities-17.28-4.74-52.0451.9811.56-23.790.0022.65
Exchange Rate Effect-0.17-0.03-0.00-0.05-0.06--0.010.010.03
Net Change in Cash-1.69-8.4745.37-31.4113.01-15.97-1.671.03
Free Cash Flow-5.82-9.15-8.43-10.55-29.20--12.52-12.96-14.66
Preferred Dividends (Cash Flow)-0.000.000.000.00-0.000.000.00
Deferred Taxes & Investment Tax Credit-7.910.000.000.00-0.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments50.6165.84125.89134.6997.94130.64
Short Term Receivables0.620.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.172.317.381.431.090.83
Total Current Assets53.4168.15133.27136.1299.03131.48
Net Property, Plant & Equipment1.151.251.341.431.531.01
Total Investments and Advances315.04199.4096.2182.9059.1413.79
Intangible Assets0.000.000.000.000.000.00
Other Assets0.050.050.050.041.991.25
Total Assets369.64268.85230.86220.49161.68147.54
Short Term Debt Incl. Current Port. of LT Debt0.250.270.280.270.260.18
Accounts Payable0.370.480.440.560.710.51
Income Tax Payable6.274.643.293.480.343.79
Other Current Liabilities3.835.1715.071.802.371.01
Total Current Liabilities10.7310.5619.096.123.695.49
Long Term Debt0.480.490.540.590.650.12
Provision for Risks Charges0.040.040.040.040.040.03
Deferred Tax Liabilities39.5417.757.917.92--
Other Liabilities1.371.733.543.503.722.00
Total Liabilities52.1730.5731.1218.168.107.64
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity317.47238.28199.74203.28154.53140.81
Total Shareholders Equity317.47238.28199.74203.28154.53140.81
Accumulated Minority Interest0.000.000.00-0.95-0.95-0.92
Total Equity317.47238.28199.74202.33153.58139.89
Total Liabilities & Stockholders Equity369.64268.85230.86220.49161.68147.54
Book Value Per Share7.685.825.094.983.783.45
Tangible Book Value Per Share7.685.825.094.983.783.45
Full-Time Employees--13---
Price to Book Ratio0.520.670.570.700.650.58
Return on Assets65.5252.4532.7622.75-13.97-16.08
Return on Equity73.7557.6136.5624.38-14.57-18.37
Return on Invested Capital24.5816.044.5923.748.56-5.42
Quick Ratio4.986.456.9822.2426.8123.94
Current Ratio4.986.456.9822.2426.8123.94

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income81.1438.3111.4250.8313.28-7.64
Depreciation0.030.030.030.030.030.03
Other Funds (Non Cash)-105.83-49.08-12.84-62.70-14.225.67
Funds from Operations7.79-10.747.01-11.83-0.91-1.95
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-8.077.82-7.639.84-2.66-1.57
Cash from Operating Activities-0.28-2.92-0.62-1.99-3.56-3.52
Capital Expenditures-0.00-0.00-0.00-0.00-0.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-8.00-7.56-0.7239.09-53.0223.62
Purchase of Investments-27.93-13.86-24.02-5.28-62.67-8.44
Sale Or Maturity of Investments19.936.3023.3044.379.6532.06
Other Uses11.92-11.92-0.96-0.27-1.960.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities3.92-19.49-1.6838.82-54.9823.62
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.00-4.26-0.39-0.370.00
Repurchase of Common Pref Stock0.000.00-4.26-0.39-0.370.00
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.35-10.360.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-1.920.000.000.000.000.00
Other Financing Activities Uses-1.920.000.000.000.000.00
Cash from Financing Activities-2.26-10.36-4.26-0.39-0.370.00
Exchange Rate Effect-0.120.02-0.080.010.04-0.00
Net Change in Cash1.26-32.75-6.6436.44-58.8820.10
Free Cash Flow-0.28-2.92-0.63-1.99-3.57-3.52

Revenue breakdown

Pharmaceutical Preparations2025: 2.00M
United States2025: 2.00M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.29%1.3M31.3M182.01K
2026-10-154.63%1.5M31.3M186.25K
2026-09-304.61%1.4M31.1M214.21K
2026-09-153.85%1.3M34.0M300.91K
2026-08-313.40%1.2M34.0M301.77K
2026-08-143.02%1.0M34.0M292.66K
2026-07-312.46%0.8M34.0M294.56K
2026-07-152.40%0.8M31.9M296.88K
2026-06-302.75%0.9M31.9M258.56K
2026-06-151.80%0.6M31.7M157.20K
2026-05-292.09%0.7M31.6M149.84K
2026-05-152.01%0.6M31.6M148.05K
2026-04-302.08%0.7M31.2M140.17K
2026-04-151.85%0.6M31.2M156.17K
2026-03-311.81%0.6M31.2M210.54K
2026-03-131.77%0.5M30.7M218.57K
2026-02-271.81%0.6M30.7M226.51K
2026-02-131.76%0.5M30.7M255.33K
2026-01-302.09%0.6M30.8M261.00K
2026-01-151.32%0.4M30.9M239.67K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.002.30-88.000.00---
call5.000.000.000.05-4140.00---
call7.500.000.000.03-18.000.00---
call10.000.000.000.00-0.000.00---
put2.500.000.000.25-3.000.00---
put5.000.000.000.16-10.000.00---
put7.500.000.003.48-4.000.00---
put10.000.000.000.00-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-178-KCurrent report2026-09-15SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-03ARSAnnual report to security holders. 2025-12-31SEC
2026-08-03DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-03DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-15SEC
2026-07-22SCHEDULE 13D/ASEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-06-308-KCurrent report2026-06-25SEC
2026-06-29SCHEDULE 13G/ASEC
2026-06-17SCHEDULE 13D/ASEC
2026-05-1910-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-15SCHEDULE 13GSEC
2026-05-15NT 10-Q2026-03-31SEC
2026-05-143Initial statement of beneficial ownership of securities2026-03-25SEC
2026-05-14SCHEDULE 13DSEC
2026-03-318-KCurrent report2026-03-25SEC
2026-03-314Statement of changes in beneficial ownership of securities2026-03-30SEC
2026-03-314Statement of changes in beneficial ownership of securities2026-03-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000225.53K2
2026-090000
2026-080000
2026-0700942.17K2
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
MERCER GLOBAL ADVISORS INC /ADV9.31%
Aquamarine Financial6.14%
Gem Investment Advisors, LLC4.88%
BlackRock, Inc.3.93%
Murchinson Ltd.3.15%
BML Capital Management, LLC2.13%
BOOTHBAY FUND MANAGEMENT, LLC1.41%
GEODE CAPITAL MANAGEMENT, LLC1.20%
GOLDMAN SACHS GROUP INC0.62%
STATE STREET CORP0.59%

Funds

Fund% owned
iShares Russell 2000 ETF1.55%
Fidelity Small Cap Index Fund0.92%
iShares Russell 2000 Value ETF0.78%
VANGUARD RUSSELL 2000 INDEX FUND0.47%
iShares Micro-Cap ETF0.28%
Schwab Small-Cap Index Fund0.20%
Master Small Cap Index Series0.16%
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF0.14%
Avantis U.S. Small Cap Equity ETF0.13%
Fidelity Small Cap Value Index Fund0.12%

OakChart. ORMP. Cached 15 minutes.